These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 32284170)
1. Structural basis of serum albumin recognition by SL335, an antibody Fab extending the serum half-life of protein therapeutics. Cho SY; Han J; Cha SH; Yoon SI Biochem Biophys Res Commun; 2020 Jun; 526(4):941-946. PubMed ID: 32284170 [TBL] [Abstract][Full Text] [Related]
2. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn Mester S; Evers M; Meyer S; Nilsen J; Greiff V; Sandlie I; Leusen J; Andersen JT MAbs; 2021; 13(1):1893888. PubMed ID: 33691596 [TBL] [Abstract][Full Text] [Related]
3. Intact bioactivities and improved pharmacokinetic of the SL335-IFN-β-1a fusion protein that created by genetic fusion of SL335, a human anti-serum albumin fab, and human interferon-β. Ji SI; Park JH; You HG; Chi HJ; Bang YW; Cha SH Immunol Lett; 2019 Mar; 207():46-55. PubMed ID: 30684504 [TBL] [Abstract][Full Text] [Related]
4. Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life. Adams R; Griffin L; Compson JE; Jairaj M; Baker T; Ceska T; West S; Zaccheo O; Davé E; Lawson AD; Humphreys DP; Heywood S MAbs; 2016 Oct; 8(7):1336-1346. PubMed ID: 27315033 [TBL] [Abstract][Full Text] [Related]
5. Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics. Andersen JT; Cameron J; Plumridge A; Evans L; Sleep D; Sandlie I J Biol Chem; 2013 Aug; 288(33):24277-85. PubMed ID: 23818524 [TBL] [Abstract][Full Text] [Related]
6. Multivalent Albumin-Neonatal Fc Receptor Interactions Mediate a Prominent Extension of the Serum Half-Life of a Therapeutic Protein. Yang B; Kwon I Mol Pharm; 2021 Jun; 18(6):2397-2405. PubMed ID: 33983743 [TBL] [Abstract][Full Text] [Related]
7. Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement. Larsen MT; Rawsthorne H; Schelde KK; Dagnæs-Hansen F; Cameron J; Howard KA J Control Release; 2018 Oct; 287():132-141. PubMed ID: 30016735 [TBL] [Abstract][Full Text] [Related]
8. Human serum albumin presents isoform variants with altered neonatal Fc receptor interactions. Leblanc Y; Berger M; Seifert A; Bihoreau N; Chevreux G Protein Sci; 2019 Nov; 28(11):1982-1992. PubMed ID: 31583777 [TBL] [Abstract][Full Text] [Related]
9. Half-life extension of efficiently produced DARPin serum albumin fusions as a function of FcRn affinity and recycling. Merten H; Brandl F; Zimmermann M; Schaefer JV; Irpinio L; Sand KMK; Nilsen J; Andersen JT; Zangemeister-Wittke U; Plückthun A Eur J Pharm Biopharm; 2021 Oct; 167():104-113. PubMed ID: 34303832 [TBL] [Abstract][Full Text] [Related]
10. Isolation of human anti-serum albumin Fab antibodies with an extended serum-half life. Kang HJ; Kim HJ; Cha SH Immunol Lett; 2016 Jan; 169():33-40. PubMed ID: 26593745 [TBL] [Abstract][Full Text] [Related]
11. Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn). Sand KM; Bern M; Nilsen J; Dalhus B; Gunnarsen KS; Cameron J; Grevys A; Bunting K; Sandlie I; Andersen JT J Biol Chem; 2014 Dec; 289(50):34583-94. PubMed ID: 25344603 [TBL] [Abstract][Full Text] [Related]
12. Design and biological evaluation of novel long-acting adalimumab Fab conjugated with the albumin binding domain. Zhang Q; Qian M; Wu Y; Wang Y; Shangguan W; Lu J; Zhao W; Feng J Eur J Pharmacol; 2021 Aug; 904():174152. PubMed ID: 33964292 [TBL] [Abstract][Full Text] [Related]
13. Half-life-extended recombinant coagulation factor IX-albumin fusion protein is recycled via the FcRn-mediated pathway. Chia J; Louber J; Glauser I; Taylor S; Bass GT; Dower SK; Gleeson PA; Verhagen AM J Biol Chem; 2018 Apr; 293(17):6363-6373. PubMed ID: 29523681 [TBL] [Abstract][Full Text] [Related]
14. Comparative studies of the serum half-life extension of a protein via site-specific conjugation to a species-matched or -mismatched albumin. Yang B; Kim JC; Seong J; Tae G; Kwon I Biomater Sci; 2018 Jul; 6(8):2092-2100. PubMed ID: 29881837 [TBL] [Abstract][Full Text] [Related]
15. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659 [TBL] [Abstract][Full Text] [Related]
16. FcRn binding properties of an abnormal truncated analbuminemic albumin variant. Andersen JT; Daba MB; Sandlie I Clin Biochem; 2010 Mar; 43(4-5):367-72. PubMed ID: 20006594 [TBL] [Abstract][Full Text] [Related]
17. Human and mouse albumin bind their respective neonatal Fc receptors differently. Nilsen J; Bern M; Sand KMK; Grevys A; Dalhus B; Sandlie I; Andersen JT Sci Rep; 2018 Oct; 8(1):14648. PubMed ID: 30279529 [TBL] [Abstract][Full Text] [Related]
18. Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface. Schmidt MM; Townson SA; Andreucci AJ; King BM; Schirmer EB; Murillo AJ; Dombrowski C; Tisdale AW; Lowden PA; Masci AL; Kovalchin JT; Erbe DV; Wittrup KD; Furfine ES; Barnes TM Structure; 2013 Nov; 21(11):1966-78. PubMed ID: 24120761 [TBL] [Abstract][Full Text] [Related]
19. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. Andersen JT; Pehrson R; Tolmachev V; Daba MB; Abrahmsén L; Ekblad C J Biol Chem; 2011 Feb; 286(7):5234-41. PubMed ID: 21138843 [TBL] [Abstract][Full Text] [Related]
20. Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs. Viuff D; Antunes F; Evans L; Cameron J; Dyrnesli H; Thue Ravn B; Stougaard M; Thiam K; Andersen B; Kjærulff S; Howard KA J Control Release; 2016 Feb; 223():22-30. PubMed ID: 26699424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]